PAFAGOLD M 1000

Description

Dapagliflozin and Metformin Hydrochloride PAFAGOLD M 1000 is a modern and highly effective oral anti-diabetic formulation that combines Dapagliflozin and Metformin Hydrochloride. This dual therapy is specifically designed for patients with Type 2 Diabetes Mellitus (T2DM) who require better glycemic control when diet and exercise alone are not sufficient. By targeting different mechanisms of blood sugar regulation, PAFAGOLD M 1000 provides comprehensive glucose management, improved insulin sensitivity, and additional metabolic benefits. Composition Each film-coated tablet contains: Dapagliflozin – A selective SGLT2 inhibitor Metformin Hydrochloride 1000 mg – A biguanide class anti-hyperglycemic agent Mechanism of Action Dapagliflozin Inhibits Sodium-Glucose Co-Transporter-2 (SGLT2) in the renal tubules. Reduces glucose reabsorption in kidneys, leading to increased urinary glucose excretion. Helps lower both fasting and postprandial blood glucose. Provides additional benefits like weight reduction and blood pressure improvement. Metformin Hydrochloride Decreases hepatic glucose production (gluconeogenesis). Improves insulin sensitivity in peripheral tissues. Enhances glucose uptake and utilization in muscles. Does not cause hypoglycemia when used alone. Together, this combination ensures synergistic control of blood glucose while also addressing insulin resistance and excess glucose reabsorption. Therapeutic Indications PAFAGOLD M 1000 is indicated for: Management of Type 2 Diabetes Mellitus (T2DM) in adults. Patients uncontrolled on Metformin monotherapy. Combination therapy with other anti-diabetic agents, if needed. Dosage and Administration Typical Dose: One tablet once or twice daily, as prescribed by a physician. Should be taken with meals to reduce gastrointestinal side effects. Dosage may be individualized based on patient response and tolerance. Key Benefits of PAFAGOLD M 1000 Dual Mechanism Control: Targets both insulin resistance and renal glucose reabsorption. Weight-Friendly Option: Dapagliflozin supports modest weight reduction. Improves Glycemic Control: Lowers HbA1c, FPG, and PPG effectively. Cardio-Renal Benefits: SGLT2 inhibitors have shown protective effects in heart and kidney health. Enhanced Patient Compliance: Convenient fixed-dose combination in a single tablet. Possible Side Effects Some patients may experience mild side effects such as: Urinary tract infections (UTIs) Genital infections (due to increased glucose in urine) Gastrointestinal discomfort (nausea, diarrhea, abdominal pain) Rare: Lactic acidosis (with Metformin, if used improperly) Precautions & Warnings Not for use in Type 1 Diabetes or diabetic ketoacidosis. Avoid in patients with severe renal impairment. Monitor liver and kidney function regularly. Use cautiously in elderly patients. Pregnant or breastfeeding women should use only under medical supervision. Conclusion PAFAGOLD M 1000 (Dapagliflozin + Metformin Hydrochloride) is an advanced anti-diabetic therapy designed to deliver effective blood glucose control, metabolic balance, and long-term health benefits. By combining two proven agents with complementary mechanisms, it stands as an ideal choice for patients struggling with uncontrolled Type 2 Diabetes Mellitus. With the trusted quality of Steris Healthcare, PAFAGOLD M 1000 empowers patients to live healthier, more active lives while keeping diabetes under control.